$ALT
Altimmune Inc

2015 Q4 Form 10-Q Financial Statement

#000114420415063377 Filed on November 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q4
Revenue $1.270M $1.160M $1.830M
YoY Change -30.6% 14499900.0% -49.86%
Cost Of Revenue -$50.00K
YoY Change
Gross Profit $1.320M
YoY Change
Gross Profit Margin 103.94%
Selling, General & Admin $980.0K $1.230M $2.620M
YoY Change -62.6% -61.44% -42.79%
% of Gross Profit 74.24%
Research & Development $1.170M $1.126M $1.790M
YoY Change -34.64% -34.88% -56.34%
% of Gross Profit 88.64%
Depreciation & Amortization $30.00K $35.01K $40.00K
YoY Change -25.0% -5.71% 0.0%
% of Gross Profit 2.27%
Operating Expenses $2.180M $2.814M $4.450M
YoY Change -51.01% -43.24% -48.97%
Operating Profit -$940.5K -$1.659M -$2.624M
YoY Change -64.15% -58.5% -48.23%
Interest Expense -$280.0K $9.888K $10.00K
YoY Change -2900.0% -78.93% -98.48%
% of Operating Profit
Other Income/Expense, Net $0.00 $349.2K $0.00
YoY Change -157.5%
Pretax Income -$1.220M -$1.309M -$2.620M
YoY Change -53.44% -71.56% -40.59%
Income Tax $20.00K $15.44K $10.00K
% Of Pretax Income
Net Earnings -$1.238M -$1.325M -$2.629M
YoY Change -52.9% -71.38% -40.57%
Net Earnings / Revenue -97.51% -114.2% -143.68%
Basic Earnings Per Share -$0.02 -$0.02 -$0.04
Diluted Earnings Per Share -$0.02 -$0.02 -$0.04
COMMON SHARES
Basic Shares Outstanding 64.45M shares 64.19M shares 63.37M shares
Diluted Shares Outstanding 64.19M shares

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.60M $17.40M $18.60M
YoY Change -16.13% -11.22% 77.14%
Cash & Equivalents $15.57M $17.39M $18.64M
Short-Term Investments $6.400M $6.400M $6.400M
Other Short-Term Assets $200.0K $200.0K $200.0K
YoY Change 0.0% -71.43% 0.0%
Inventory
Prepaid Expenses
Receivables $1.500M $700.0K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.23M $18.25M $19.25M
YoY Change -10.51% -11.37% 34.25%
LONG-TERM ASSETS
Property, Plant & Equipment $233.7K $248.3K $325.8K
YoY Change -28.26% -31.5% -15.62%
Goodwill $22.49M $2.348M $2.348M
YoY Change 857.85% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.38K $53.38K $53.38K
YoY Change 0.0% 0.0% -18.7%
Total Long-Term Assets $2.636M $2.650M $2.728M
YoY Change -3.38% -4.13% -2.59%
TOTAL ASSETS
Total Short-Term Assets $17.23M $18.25M $19.25M
Total Long-Term Assets $2.636M $2.650M $2.728M
Total Assets $19.86M $20.90M $21.98M
YoY Change -9.63% -10.51% 28.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $521.1K $306.2K $391.4K
YoY Change 33.14% 8.56% -65.31%
Accrued Expenses $1.600M $2.100M $1.200M
YoY Change 33.33% -19.23% -62.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $746.1K
YoY Change -100.0% -25.39%
Total Short-Term Liabilities $2.179M $2.381M $2.582M
YoY Change -15.58% -38.72% -62.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $433.4K $431.0K $493.1K
YoY Change -12.11% -15.0% -16.24%
Total Long-Term Liabilities $433.4K $431.0K $493.1K
YoY Change -12.11% -15.0% -62.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.179M $2.381M $2.582M
Total Long-Term Liabilities $433.4K $431.0K $493.1K
Total Liabilities $3.213M $3.224M $3.704M
YoY Change -13.25% -38.52% -62.22%
SHAREHOLDERS EQUITY
Retained Earnings -$223.7M -$222.5M -$220.3M
YoY Change 1.56% 2.22% 4.73%
Common Stock $6.438K $240.2M $238.8M
YoY Change -100.0% 1.77% 9.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.13M $17.67M $18.27M
YoY Change
Total Liabilities & Shareholders Equity $19.86M $20.90M $21.98M
YoY Change -9.63% -10.51% 28.23%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q4
OPERATING ACTIVITIES
Net Income -$1.238M -$1.325M -$2.629M
YoY Change -52.9% -71.38% -40.57%
Depreciation, Depletion And Amortization $30.00K $35.01K $40.00K
YoY Change -25.0% -5.71% 0.0%
Cash From Operating Activities -$1.830M -$1.330M -$3.520M
YoY Change -48.01% -37.26% -43.77%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$10.00K $0.00
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$20.00K -$10.00K $0.00
YoY Change 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K 310.0K 2.550M
YoY Change -98.82% -97.05% 222.78%
NET CHANGE
Cash From Operating Activities -1.830M -1.330M -3.520M
Cash From Investing Activities -20.00K -10.00K 0.000
Cash From Financing Activities 30.00K 310.0K 2.550M
Net Change In Cash -1.820M -1.030M -970.0K
YoY Change 87.63% -112.31% -82.27%
FREE CASH FLOW
Cash From Operating Activities -$1.830M -$1.330M -$3.520M
Capital Expenditures -$20.00K -$10.00K $0.00
Free Cash Flow -$1.810M -$1.320M -$3.520M
YoY Change -48.58% -37.44% -43.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
196478 USD
CY2015Q3 us-gaap Assets Current
AssetsCurrent
18245550 USD
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248270 USD
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53384 USD
CY2015Q3 us-gaap Goodwill
Goodwill
2348453 USD
CY2015Q3 us-gaap Assets
Assets
20895657 USD
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
306172 USD
CY2015Q3 pip Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1453123 USD
CY2015Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
619119 USD
CY2015Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
70326 USD
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2380769 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2581789 USD
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
431015 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
493137 USD
CY2015Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
227898 USD
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
629170 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17389409 USD
CY2015Q3 us-gaap Liabilities
Liabilities
3223700 USD
CY2014Q4 us-gaap Liabilities
Liabilities
3704096 USD
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64358834 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63603303 shares
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
6436 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
6360 USD
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
240151146 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
238780633 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18643351 USD
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
USD
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222485625 USD
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
17671957 USD
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20895657 USD
CY2015Q3 us-gaap Billed Contract Receivables
BilledContractReceivables
USD
CY2015Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
659663 USD
CY2014Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
297431 USD
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64358834 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63858500 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55577550 shares
us-gaap Contracts Revenue
ContractsRevenue
9374155 USD
us-gaap Contracts Revenue
ContractsRevenue
8363909 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7528616 USD
us-gaap Restructuring Charges
RestructuringCharges
2519273 USD
us-gaap Restructuring Charges
RestructuringCharges
USD
us-gaap Depreciation
Depreciation
113272 USD
us-gaap Interest Expense
InterestExpense
48492 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
577426 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
464703 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6594 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1470 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
306336 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
289877 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2155995 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7277890 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46310 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
48105 USD
us-gaap Net Income Loss
NetIncomeLoss
-2202305 USD
us-gaap Net Income Loss
NetIncomeLoss
-7325995 USD
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
1155839 USD
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
962451 USD
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1125865 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3192427 USD
CY2015Q3 us-gaap Restructuring Charges
RestructuringCharges
422482 USD
CY2015Q3 us-gaap Depreciation
Depreciation
35005 USD
CY2014Q3 us-gaap Depreciation
Depreciation
37125 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
2814387 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
4958481 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1658548 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3996030 USD
CY2015Q3 us-gaap Interest Expense
InterestExpense
9888 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
46930 USD
CY2015Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
359796 USD
CY2014Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-560487 USD
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-691 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
80 USD
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
349217 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-607337 USD
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1309331 USD
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58952731 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64187618 shares
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4603367 USD
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15437 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25068 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1324768 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-4628435 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15341264 USD
CY2015Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1922781 shares
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
193594 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14182852 USD
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Trading Symbol
TradingSymbol
PIP
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
169 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-7585 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1387028 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4951585 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
68277 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92269 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7600 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-60677 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-84269 USD
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-750007 USD
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-749997 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1091740 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
943601 USD
CY2014Q3 us-gaap Restructuring Charges
RestructuringCharges
USD
CY2015Q3 pip Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation
OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation
USD
CY2014Q3 pip Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation
OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation
USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
336 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7162 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1972777 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7333157 USD
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5869 USD
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1324768 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4634304 USD
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
USD
us-gaap Share Based Compensation
ShareBasedCompensation
426988 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1172703 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
46310 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
48105 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
-51820 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
68130 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7600 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5393 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-110656 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1427113 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
362232 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-1895858 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9602 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23869 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-85175 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-846090 USD
us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
800769 USD
us-gaap Restructuring Reserve Period Increase Decrease
RestructuringReservePeriodIncreaseDecrease
USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
149438 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-773517 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-284937 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1253942 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9139413 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10480979 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19620392 USD
us-gaap Interest Paid
InterestPaid
108134 USD
us-gaap Interest Paid
InterestPaid
105916 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
426988 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
112000 shares
pip Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod
117500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1357755 shares
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000 USD
CY2015Q3 pip Billed And Unbilled Accounts Receivable Net
BilledAndUnbilledAccountsReceivableNet
700000 USD
CY2015Q3 pip Additional Common Stock Aggregate Gross Sales
AdditionalCommonStockAggregateGrossSales
3000000 USD
CY2015Q1 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2000000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10900000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Use of Estimates</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></p> </div>
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
683325 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36981 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
USD
CY2015Q3 pip Proceeds From Additional Funding
ProceedsFromAdditionalFunding
2300000 USD
CY2015Q3 pip Annual License Payment
AnnualLicensePayment
200000 USD
pip Share Based Compensation Extension Of Exercise Period
ShareBasedCompensationExtensionOfExercisePeriod
75000 USD
pip Share Based Compensation Reversal From Stock Option Forfeitures
ShareBasedCompensationReversalFromStockOptionForfeitures
129000 USD
pip Share Based Compensation Reversal Net
ShareBasedCompensationReversalNet
53741 USD
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93757 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280720 USD
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
100000 shares
pip Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod
shares
CY2015Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
230253 USD
CY2015Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
113000000 USD
CY2015Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
194600000 USD
CY2015Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
113100000 USD
CY2015Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
81500000 USD
CY2009Q3 pip Warrant Expiration Date
WarrantExpirationDate
2015-01-28
dei Entity Registrant Name
EntityRegistrantName
PHARMATHENE, INC
dei Entity Central Index Key
EntityCentralIndexKey
0001326190
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64451334 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
USD
CY2015Q3 us-gaap Accrued Rent Current
AccruedRentCurrent
244769 USD
CY2015Q3 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
184018 USD
CY2015Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2355 USD
CY2015Q3 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
184018 USD
CY2014Q4 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
USD
CY2015Q3 pip Maximum Amount Of Reimbursement
MaximumAmountOfReimbursement
210000 USD
CY2015Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36981 USD
CY2015Q3 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
0 USD
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
178509 USD
CY2014Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
807679 USD

Files In Submission

Name View Source Status
0001144204-15-063377-index-headers.html Edgar Link pending
0001144204-15-063377-index.html Edgar Link pending
0001144204-15-063377.txt Edgar Link pending
0001144204-15-063377-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pip-20150930.xml Edgar Link completed
pip-20150930.xsd Edgar Link pending
pip-20150930_cal.xml Edgar Link unprocessable
pip-20150930_def.xml Edgar Link unprocessable
pip-20150930_lab.xml Edgar Link unprocessable
pip-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v422632_10q.htm Edgar Link pending
v422632_ex31-1.htm Edgar Link pending
v422632_ex31-2.htm Edgar Link pending
v422632_ex32-1.htm Edgar Link pending
v422632_ex32-2.htm Edgar Link pending